Author: Merrel Briona

Mogrify Limited (Mogrify^®), a regenerative medicine company developing a novel class of in vivo reprogramming therapies, today announced it will present preclinical proof-of-concept data at FLORetina-ICOOR 2026. The data support its first-in-class therapy designed to protect and regenerate the retina in patients with retinal disorders.

The company’s lead program uses transcription factor-mediated direct reprogramming to convert müller glial cells into functional photoreceptors within the retina. By addressing the photoreceptor loss underlying retinal degeneration, the approach aims to preserve and regenerate retinal function and restore clinically meaningful vision in patients with a range of retinal disorders.

In a recently completed large-scale preclinical proof-of-concept study, Mogrify demonstrated statistically significant preservation and restoration of visual function across multiple functional endpoints in a rodent model of induced retinal degeneration. The study used AAV-delivered combinations of transcription factors identified through the Company’s proprietary platform.

Mogrify’s platform combines next-generation sequencing and a human gene regulatory network-based approach to systematically and impartially identify optimal transcription factor combinations for controlling human cell fate. The technology enables direct in vivo conversion between any source cell type and any target cell type of clinical interest.

Chief Scientific Officer at Mogrify, Dr. Jonathan Appleby, will lead the program towards first-in-human studies, bringing 30 years of medicines development expertise. Mogrify is actively seeking partners to support the program’s advancement.

We are thrilled to have generated statistically robust evidence that AAV delivery of MOGRIFY-identified transcription factor combinations can both protect against and reverse vision loss in a preclinical model of retinal degeneration. Demonstrated across several dosing formats and multiple functional endpoints, these findings represent an important step towards the development of a fundamentally novel and gene-agnostic approach to treating retinal disease.”

Dr. Jonathan Appleby, Chief Scientific Officer, Mogrify 

Joe Foster, Chief Executive Officer, Mogrify, added: “These results are an exciting milestone, providing a robust foundation for advancing our lead program towards clinical development. We are now exploring licensing and investment opportunities to progress this asset into first-in-human studies.”

The presentation, Delivery of a selected combination of transcription factors can improve visual function in a preclinical model of retinal degeneration, will be given at the FLORetina-ICOOR 2026 Congress, taking place 3-6 December 2026.

• Presentation Track: IRD 1 – Natural History, Endpoints & Therapies
• Presentation Date: Thursday, 3 December 2026
• Presentation Time: 12:00-13:00

The data will also be presented as part of The Dolphin Tank, EYENOVATE’s premier ophthalmology and vision science innovation showcase, hosted during FLORetina-ICOOR 2026.

Dec 1, 11 AM ET. See what’s actually exploitable.

Your DAST just found 400 issues. Which three could an attacker actually use?

Find out live on December 1. We’re pointing
Pentera
Apps at a running web application and letting it work in front of you. This isn’t a scanner running a checklist; it’s an agent reasoning its way through the app.

• Logic, not signatures. Watch it manipulate state, sequence requests, and adapt payloads across multi-step workflows.
• Low-severity becomes a path. An info disclosure plus an IDOR becomes an account takeover, chained and validated end-to-end.
• It knows where to stop. Customer-defined scope, deterministic guardrails, full audit trail. Watch it refuse to cross a boundary in production.
• Evidence your developers won’t argue with. Replayable exploits, reproduction steps, and request/response traces, ready for a ticket.

December 1, 2026 | 11:00 AM ET / 4:00 PM GMT | 60 minutes

Test everything. Fix faster.

P.S. Want to experience Pentera Apps for yourself? Get on the early access waitlist HERE

Sony Semiconductor Solutions has confirmed that its flagship IMX927 global shutter image sensor has entered mass shipment. The sensor delivers approximately 105 megapixels at up to 102 frames per second in 10-bit, or 72.8 FPS in 12-bit, at full resolution. The announcement marks a commercial milestone for one of Sony’s most ambitious high-resolution global shutter imaging technologies.

Sony originally announced the IMX927 in September 2025, introducing a 105MP stacked CMOS sensor designed primarily for industrial imaging, machine vision, and advanced inspection systems. As YMCinema reported in October 2025, the IMX927 combines a 10K-class square imaging area, a 39.7mm diagonal, and global shutter technology capable of capturing fast-moving subjects without rolling shutter distortion. Sony subsequently demonstrated the sensor’s capabilities, as covered by YMCinema in January 2026. Now, according to a November 11, 2026 product communication distributed by Sony Semiconductor Solutions, the monochrome IMX927 entered mass shipment in October 2026. The distinction is important. The performance specifications are not new, but the sensor has progressed from its initial announcement and demonstration stage to mass production.

The newly supplied IMX927-AQB technical flyer details the capabilities of the sensor’s color variant. With a recommended recording resolution of 10,240 × 10,240 pixels, the IMX927 supports three full-resolution output modes:

• 8-bit: 111.7 FPS
• 10-bit: 102 FPS
• 12-bit: 72.8 FPS

The sensor features 2.74μm pixels and Sony’s Pregius S stacked, back-illuminated global shutter technology. It also supports a 5,120 × 5,120 subsampling mode reaching 200 FPS in 10-bit or 143.2 FPS in 12-bit. The interface is equally significant. Sony uses SLVS-EC high-speed connections capable of supporting approximately 100 Gbps of aggregate data transfer bandwidth, addressing the enormous throughput requirements of 105MP imaging at triple-digit frame rates. Sony’s latest shipment confirmation specifically concerns the monochrome version, while the accompanying IMX927-AQB flyer describes the color version. The communication does not establish a new mass-shipment date for the color model.

The IMX927 is particularly interesting when compared with Sony’s IMX937, another 105MP global shutter sensor with the same 39.7mm diagonal. As YMCinema detailed in October 2026, the IMX937 reaches approximately 36 FPS at 12-bit full resolution. By comparison, the IMX927 achieves 72.8 FPS at 12-bit, representing approximately twice the throughput at comparable resolution. At 10-bit, the difference is similarly substantial: 102 FPS for the IMX927 compared with 51 FPS for the IMX937. This demonstrates how Sony is developing distinct high-resolution global shutter sensors with different readout capabilities, even when their fundamental imaging dimensions are identical.

The IMX927 remains an industrial image sensor, with applications focused on factory automation, precision inspection, and 3D vision rather than digital cinema. Nevertheless, the underlying technology is relevant to professional filmmaking. Capturing more than 100 million pixels at approximately 73 FPS in 12-bit while maintaining a global shutter demonstrates a level of readout performance that remains highly ambitious for professional cinema cameras. The sensor’s square format also presents interesting possibilities for cropping, reframing, and high-resolution motion capture, although its 39.7mm diagonal should not be confused with the dimensions of a conventional 36 × 24mm full-frame sensor. There are also substantial unanswered questions concerning dynamic range, color performance, processing requirements, and recording infrastructure in a potential cinema application. Sony has not announced any plans to integrate the IMX927 into its Cinema Line or CineAlta cameras. However, the IMX927’s unusual 1:1 sensor geometry offers intriguing possibilities for anamorphic cinematography. A 2× anamorphic lens could theoretically produce a 2:1 image while utilizing the sensor’s full 10K vertical resolution. Combined with global shutter readout and 12-bit capture at 72.8 FPS, the sensor presents an interesting technological foundation for future large-format imaging systems.

The significance of Sony’s latest announcement is not another record-breaking sensor specification, but the transition of its 105MP, high-speed global shutter technology into commercial mass production. With approximately 10K resolution, 102 FPS at 10-bit, and 72.8 FPS at 12-bit, the IMX927 demonstrates what Sony’s industrial semiconductor division can already deliver. Whether comparable technology eventually appears in a dedicated cinema camera remains an open question. For now, the IMX927 provides an interesting benchmark for the next generation of ultra-high-resolution global shutter imaging.